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This practice is based on reported experience from single 
institutions. 
In the first decade of the 21st century, local control using 
stereotactic radiotherapy or surgical resection of individual 
brain metastases has emerged as a clinically beneficial 
modality for highly selected patients. Whole brain 
radiotherapy is increasingly seen as a treatment provided in 
addition to this local control, or is held in reserve for salvage 
management should new or recurrent brain metastases 
develop at a later date – without RCT evidence supporting 
this approach (4,5,6).  
The majority of patients with brain metastases, however, are 
not suitable for stereotactic or surgical approaches and WBRT 
continues to be seen as the standard of care for this group, 
particularly if they are perceived to have a durable prognosis 
(5). Until the MRC QUARTZ trial was undertaken in non-small 
cell lung cancer (NSCLC) (Mulvenna et al 2016-in press), there 
were no sufficiently powered randomised controlled trials 
specifically addressing the utility of WBRT compared to 
supportive care (7).  
Although prophylactic cranial irradiation has enhanced 
overall survival and reduced incidence of brain metastases 
for patients with the exquisitely radiosensitive small cell 
variant of lung cancer, trials addressing this issue in NSCLC 
and Breast cancer have failed to accrue. This lack of high 
quality evidence added to the fear of neurocognitive decline 
remains a potential barrier to applying this technique to 
other solid tumours with a propensity for metastasising to the 
brain. 
 
Questions to address: 
Can we apply prognostic indices reliably to all solid tumour 
types? 
Do we really know which patients will benefit from WBRT, 
whether used as a sole palliative modality or as an adjunct to 
local (stereotactic or surgical) modalities?  
If so, how can we best use Image Guided radiotherapy to 
minimise long term neurocognitive impact? 
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Brain metastases (BM) develop in up to 30% of patients with 
cancer. There is marked heterogeneity in outcomes for 
patients with BM, and these outcomes vary not only by 
diagnosis, but also by diagnosis-specific prognostic factors; 
we should not treat all patients with brain metastases the 
same way, treatment should be individualized. 
Phase III randomized trials have shown that upfront whole 
brain radiotherapy (WBRT) may decrease brain recurrence 
both in terms of better local and improved distant brain 
tumour control rate, and that neurological death rate may be 
reduced in patients treated with WBRT + stereotactic 
radiosurgery (SRS), but no survival benefit is reached. The 
EORTC 22952-26001 study (Kocher M et al) shows that 
adjuvant WBRT fails to improve the duration of functional 
independence. 
The use of SRS in the treatment of multiple BM has increased 
dramatically during the past decade to avoid the 
neurocognitive dysfunction induced by WBRT. 
One of the biggest (1194 patients) multi-institutional 
prospective observational studies (JLGK0901, Yamamoto M et 
al and Watanabe S et al) including patients with multiple BM 
(even more than 10) have shown that SRS without WBRT in 
patients with five to ten BM is non-inferior to that in patients 
with two to four BM in terms of median OS (10,8 months for 
both groups), 1-year local recurrence (6,5% and 7%), with a 
very low incidence of side effects (less than 3%). They also 
concluded that carefully selected patients with 10 or more 
BM are not unfavourable candidates for SRS alone, having 
these patients a median survival time and neurological death-
free survival times comparables to the group with 9-10 BM; 
their results suggest also that even among patients 80 years 
and older, those with modified-RPA Class I+IIa or IIb disease 
are considered to be favourable candidates for more 
aggressive treatment of BM. 
SRS has been an option for limited (1-3) metastatic brain 
lesions, and nowadays the updated guidelines (for example, 
the NCCN panel) have recently added SRS as a primary 
treatment option for multiple (>3) metastatic lesions. 
The exclusive SRS approach for patients with multiple BM is 
mostly curative for each treated lesion, it can be repeated 
several times (the limits in terms of median cumulative dose 
to the normal brain must be explored), and WBRT remains an 
option as salvage treatment. 
Exclusive SRS with frequent magnetic resonance imaging-
based follow-ups (every 2-3 months) in order to salvage 
recurrent BM before symptomatic manifestations, should be 
routinely offered to selected patients as a treatment option 
to consider (Lester SC et al). Initial treatment with a 
combination of SRS and close clinical monitoring should be 
recommended as the preferred treatment strategy to better 
preserve learning and memory in good prognosis patients 
with newly diagnosed BM (Chang EL et al). 
The Lausanne University Hospital (CHUV) has created a brain 
metastases clinic to provide medical and radiation oncology, 
neurosurgical, and supportive services to this complex 
patient population. During the first 18 months, 250 cases 
were discussed, 55% of patients had more than one brain 
metastases, and focal treatments were proposed in 69% of 
treated cases (for 50% of them radiosurgery or fractionated 
stereotactic radiotherapy, FSRT). WBRT was proposed to only 
16% of patients (some of them as salvage therapy after 
sequential treatments with SRS). 
Higher BM burden (in terms of size and volume) and higher 
integral SRS dose to the brain are the main predictive factors 
for late toxicity after SRS. The cumulative neurocognitive 
effect of numerous SRS sessions remains unknown. In order to 
reduce the cumulative median dose to the brain, the SRS 
technique must be carefully chosen. 
At CHUV, we have performed a dosimetric comparison study 
in cases with multiple brain metastases (up to 10), comparing 
a radiosurgical planning (same dose and isodose prescription) 
with Gamma Knife (GK), CyberKnife (CK), VMAT and Helical 
Tomotherapy (HT). Gradient index was better with GK and CK 
(3.4 and 4.1, compared to 17.8 and 19), as well as PTV 
coverage (100% with GK and CK, compared to 97% with VMAT 
and 90% with HT); brain Dmean was lower with GK (3 Gy) and 
CK (2.66 Gy), compared to VMAT (6.4 Gy) and HT (6.72 Gy). 
SRS alone should be considered a routine treatment option in 
patients with multiple BM due to favourable neurocognitive 
outcomes, less risk of late side effects, without adversely 
affecting the patients performance status. 
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Median survival of patients with brain dissemination in the 
course of solid tumors typically ranges between 3 and 6 
months, depending on several prognostic factors. In order to 
select patients for most appropriate treatment or best 
supportive care, several prognostic indices were proposed, of 
which recursive partitioning analysis (RPA) score and graded 
prognostic assessment (GPA) are most widely used. In 
patients with good prognosis and limited number of 
metastatic lesions, aggressive local treatment, including 
surgery and radiosurgery is common, with median survival 
approaching 12 months. Patients in the intermediate group 
are typically managed with whole brain radiotherapy (WBRT), 
whereas patients with poor prognosis are typically offered 
best supportive care. Advances in the systemic therapy of 
several malignancies have changed this picture, particularly 
in subsets of patients with driving molecular aberrations, 
such as ALK rearranged non-small cell lung cancer or BRAF 
mutant melanoma. In these patients, long-term responses in 
the brain and other tumor locations are documented, with 
series of patients being alive and well for several years after 
treatment commencement. Penetration of novel targeted 
agents to CNS becomes its critical feature, as demonstrated 
by relatively poor intracranial control for ALK inhibitor 
crizotinib vs. new generation ALK inhibitors such as alectinib. 
The activity of immunotherapy (anti-CTLA4 and checkpoint 
inhibitors) in patients with brain metastases is less well 
documented, but also appears substantial in patients who do 
not require steroids. Paradoxically, at some point of time, 
aggressive local treatment strategies and WBRT remain 
important options in patients with prolonged intracranial 
control on systemic therapy to improve treatment results 
even further. The optimal management of these patients 
remains challenging due to limited evidence-based data and 
requires multidisciplinary approach. 
 
Symposium: Radiotherapy “autovaccination” with systemic 
immune modulators for modern immunotherapy  
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Radiation therapy is an important part of oncological 
treatment for advanced and metastatic patients and is widely 
employed, usually in combination with other treatment 
modalities. Several strategies have been developed to 
increase the therapeutic index of radiation therapy, in order 
to maximize its antitumour activity or radiosensitation and, 
at the same time, limiting its cytotoxic effects on normal 
tissues or radioprotection.  
Radiation therapy includes new, high precision, low toxicity, 
treatments as SRS and SBRT. The paradigm of a systemic 
treatment alone for systemic disease, has been clearly 
changed over the last decade, as SRS/SBRT achieved 
unexpectedly (90%) high rates of local control for metastasis 
and different tumor primary locations. High doses of 
radiotherapy can now be delivered with high precision and 
very limited toxicity, therefore increasing the opportunities 
for treating patients in combination with systemic treatments 
without compromising tolerance. Such excellent responses do 
not completely fit the standard radiobiology models, based 
on well-known classical DNA damage and tumor cell kill, 
described by the "4 R's" of radiobiology (Reassortment, 
Reoxygenation, Repair, and Repopulation). Some non-
targeted effects seem to be involved and preclinical 
radiobiological studies have suggested that they may be 
immune-mediated. Either local bystander or distant abscopal 
effects could explain part of the unexpected results of 
radiotherapy. In fact, local radiotherapy appears to be a 
powerful tool for autovaccinating the patient by modifying 
the highly immunosuppressive microenvironment of 
established cancers. These pro-immunogenic effects of 
ionizing radiation on the tumor microenvironment, include 
potentiated innate and adaptive immune responses through 
release of pro-inflammatory molecules and modifications in 
MHC and adhesion molecules in cancer cells, stroma and 
endothelium. Therefore radiation therapy elicits immune 
responses as part of its role for killing cancer cells.  
Unfortunately the abscopal effect is uncommonly observed in 
clinical practice with radiotherapy alone. Although there is a 
clear contribution of the immune system to eradication of 
tumours by novel systemic immunotherapy, only a subset of 
patients benefit from these therapeutic approaches. The 
preexisting immune microenvironment seems to be an 
important predictor of response to such treatments. The 
increase of productive immune synapses induced by 
radiation, could be required for the local therapeutic 
responses to immune agents. In that scenario, changes 
induced by radiotherapy could modify the immune 
microenviroment of the tumour, improving response to 
systemic immune treatments. On the other hand, novel 
systemic immune treatments could increase the rate of 
abscopal responses observed after radiotherapy.  
Radioimmunotherapy seems to be an excellent approach for 
cancer. In fact, responses and improved outcomes are 
continuously reported in highly resistant tumours and could 
be hypothetized to provide a “broad spectrum” treatment for 
advanced cancer. In that case, modern systemic 
immunotherapy could represent the most recent form of 
radiosensitizing tumour cells and increase the radiation 
induced abscopal effect.  
We could anticipate that in the next few years radiation-
driven immunotherapy will be systematically used in 
combinations with new agents. But, to be responsible of a 
treatment, we must be aware of the potential acute and late 
toxicity issues. As for other radiosensitizing treatments, we 
should also know the best supportive treatment to manage 
such adverse events. At present anti-CTLA-4 and anti-PD-
1/PD-L1 antibodies are becoming increasely used in clinical 
practice and clinical trials.  
Although several reports showed no increase expected 
toxicity in combination with radiotherapy, these drugs are 
associated with immune-related adverse events (irAEs). irAEs 
are believed to arise from general immunologic enhancement 
and affect the dermatologic, gastrointestinal, hepatic, 
endocrine, and other organ systems. Temporary 
immunosuppression with corticosteroids, tumor necrosis 
factor-alpha antagonists or other agents can be effective 
treatment.  
As oncologists, radioimmunetherapy should be part of our 
field of knowledge and must be rapidly incorporated to our 
clinical practice. 
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Elimination of virally-infected epithelial cells is mediated by 
CD8+ T cells and results in life-long protective immunity 
against reinfection. Similarly, clinical data have shown that 
CD8+ T cells mediate the rejection of solid tumors and can 
confer long-term protection from disease recurrence when 
their activity is unleashed by immune checkpoint inhibitors. 
Like viral proteins, mutated proteins expressed by an 
individual tumor are a source of powerful tumor-specific T 
cell epitopes. However, most of the cancer patients do not 
develop a sufficient number and repertoire of tumor-reactive 
T cells and are unresponsive to currently available 
immunotherapies.  
We have pioneered studies to explore the use of local tumor 
radiotherapy (RT) as a means to release tumor antigens in an 
immunogenic context. We demonstrated that RT converted 
an insensitive mouse carcinoma into one responsive to CTLA-4 
blockade (Demaria et al., Clin Cancer Res 2005), and have 
recently shown that this combination is effective in lung 
cancer patients (NCT02221739), a carcinoma unresponsive to 
anti-CTLA-4 monotherapy. Unique changes in T cell receptor 
(TCR) repertoire of intra-tumoral CD8 T cells were observed 
